210 related articles for article (PubMed ID: 8638647)
1. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin.
Amiral J; Peynaud-Debayle E; Wolf M; Bridey F; Vissac AM; Meyer D
Am J Hematol; 1996 Jun; 52(2):90-5. PubMed ID: 8638647
[TBL] [Abstract][Full Text] [Related]
2. [Platelet factor 4, target of anti-heparin antibodies: application to biological diagnosis of heparin-induced thrombopenia].
Amiral J
Ann Med Interne (Paris); 1997; 148(2):142-9. PubMed ID: 9238439
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.
Amiral J; Bridey F; Wolf M; Boyer-Neumann C; Fressinaud E; Vissac AM; Peynaud-Debayle E; Dreyfus M; Meyer D
Thromb Haemost; 1995 Jan; 73(1):21-8. PubMed ID: 7740492
[TBL] [Abstract][Full Text] [Related]
4. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.
Cines DB; Rauova L; Arepally G; Reilly MP; McKenzie SE; Sachais BS; Poncz M
J Clin Apher; 2007 Feb; 22(1):31-6. PubMed ID: 17285619
[TBL] [Abstract][Full Text] [Related]
5. Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery.
Selleng S; Malowsky B; Itterman T; Bagemühl J; Wessel A; Wollert HG; Warkentin TE; Greinacher A
Am Heart J; 2010 Aug; 160(2):362-9. PubMed ID: 20691844
[TBL] [Abstract][Full Text] [Related]
6. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.
Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA
Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726
[TBL] [Abstract][Full Text] [Related]
7. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
[TBL] [Abstract][Full Text] [Related]
8. Heparin-induced thrombocytopenia.
Fabris F; Luzzatto G; Stefani PM; Girolami B; Cella G; Girolami A
Haematologica; 2000 Jan; 85(1):72-81. PubMed ID: 10629596
[TBL] [Abstract][Full Text] [Related]
9. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia.
Juhl D; Eichler P; Lubenow N; Strobel U; Wessel A; Greinacher A
Eur J Haematol; 2006 May; 76(5):420-6. PubMed ID: 16466367
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia.
Legnani C; Cini M; Pili C; Boggian O; Frascaro M; Palareti G
Thromb Haemost; 2010 Aug; 104(2):402-9. PubMed ID: 20539902
[TBL] [Abstract][Full Text] [Related]
11. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?
Warkentin TE; Sheppard JA; Moore JC; Moore KM; Sigouin CS; Kelton JG
J Lab Clin Med; 2005 Dec; 146(6):341-6. PubMed ID: 16310517
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis.
Carrier M; Knoll GA; Kovacs MJ; Moore JC; Fergusson D; Rodger MA
Thromb Res; 2007; 120(2):215-20. PubMed ID: 17098277
[TBL] [Abstract][Full Text] [Related]
13. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs.
Walenga JM; Jeske WP; Prechel MM; Bacher P; Bakhos M
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():69-80. PubMed ID: 15085468
[TBL] [Abstract][Full Text] [Related]
14. Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up.
Mattioli AV; Bonetti L; Zennaro M; Ambrosio G; Mattioli G
Am Heart J; 2009 Mar; 157(3):589-95. PubMed ID: 19249435
[TBL] [Abstract][Full Text] [Related]
15. Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems.
Chilver-Stainer L; Lämmle B; Alberio L
Thromb Haemost; 2004 Feb; 91(2):276-82. PubMed ID: 14961154
[TBL] [Abstract][Full Text] [Related]
16. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.
Greinacher A; Pötzsch B; Amiral J; Dummel V; Eichner A; Mueller-Eckhardt C
Thromb Haemost; 1994 Feb; 71(2):247-51. PubMed ID: 8191407
[TBL] [Abstract][Full Text] [Related]
17. Thrombotic events in patients with antiplatelet factor 4/heparin antibodies.
Mattioli AV; Bonetti L; Carletti U; Ambrosio G; Mattioli G
Heart; 2009 Aug; 95(16):1350-4. PubMed ID: 19482851
[TBL] [Abstract][Full Text] [Related]
18. Antigens involved in heparin-induced thrombocytopenia.
Amiral J
Semin Hematol; 1999 Jan; 36(1 Suppl 1):7-11. PubMed ID: 9930557
[TBL] [Abstract][Full Text] [Related]
19. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome.
Matsuo T; Tomaru T; Kario K; Hirokawa T;
Thromb Res; 2005; 115(6):475-81. PubMed ID: 15792678
[TBL] [Abstract][Full Text] [Related]
20. Testing for heparin-induced thrombocytopenia antibodies.
Warkentin TE; Sheppard JA
Transfus Med Rev; 2006 Oct; 20(4):259-72. PubMed ID: 17008164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
